{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:04:03Z","timestamp":1792728243715,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T00:00:00Z","timestamp":1520208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.diagmicrobio.2017.12.020","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T03:37:24Z","timestamp":1514950644000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015)"],"prefix":"10.1016","volume":"91","author":[{"given":"M.A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0005","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1128\/JCM.42.7.3356-3358.2004","article-title":"Quality control guidelines for BAL9141 (RO 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used","volume":"42","author":"Anderegg","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0015","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1128\/AAC.49.10.4210-4219.2005","article-title":"Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin","volume":"49","author":"Bogdanovich","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1744-8603-9-58","article-title":"Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model","volume":"9","author":"Brogan","year":"2013","journal-title":"Glob Health"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0030","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1128\/AAC.05004-14","article-title":"Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus","volume":"59","author":"Chan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0035","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","article-title":"M07-A10","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0040","series-title":"Performance standards for antimicrobial susceptibility testing: 27th informational supplement","article-title":"M100-S27","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0045","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0050","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.00029-07","article-title":"Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae","volume":"51","author":"Davies","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3201\/eid2302.152042","article-title":"Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities","volume":"23","author":"Denning","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0060","series-title":"European Committee on Antimicrobial Susceptibility Testing","article-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, January 2017","author":"EUCAST","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0065","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.02465-14","article-title":"Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2005-2006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0732-8893(01)00318-2","article-title":"Determining the value of antimicrobial surveillance programs","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0080","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(15)00474-2","article-title":"Access to effective antimicrobials: a worldwide challenge","volume":"387","author":"Laxminarayan","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0085","first-page":"4565","article-title":"Ceftobiprole for the treatment of pneumonia: a European perspective","volume":"9","author":"Liapikou","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0095","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with our without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalization","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QCO.0000000000000182","article-title":"The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria","volume":"28","author":"Perez","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijantimicag.2016.06.014","article-title":"A One Health approach to antimicrobial resistance surveillance: is there a business case for it?","volume":"48","author":"Queenan","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jac\/dkq397","article-title":"Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study","volume":"66","author":"Rossolini","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0120","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s40265-014-0273-x","article-title":"Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia","volume":"74","author":"Syed","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.diagmicrobio.2010.10.032","article-title":"In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study","volume":"69","author":"Walkty","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0130","series-title":"Summary of product characteristics","author":"Zevtera","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2017.12.020_bb0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317304169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317304169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T19:24:56Z","timestamp":1535138696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317304169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0732889317304169"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.12.020","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}